This underscores a BRD4-specific role in anti-tumor immunity, further supported by adoptive transfer studies, where BRD4 inhibition via the BRD4–p300 axis enhanced BATF expression, improving persistence and anti-tumor activity in adoptive T cell and CAR-T models (143). This evidence concerns the gene EP300 and neoplasm.